Call Options

3 transactions
Quarter Operation Price Per call calls change calls Held SEC Form
Q4 2023

Feb 13, 2024

BUY
$12.46 - $29.95 $130,830 - $314,475
10,500 Added 21.69%
58,900 $1.75 Million
Q3 2023

Nov 13, 2023

BUY
$14.09 - $19.87 $4,227 - $5,961
300 Added 0.62%
48,400 $768,000
Q2 2023

Aug 11, 2023

BUY
$3.75 - $20.05 $180,375 - $964,405
48,100 New
48,100 $907,000

Others Institutions Holding IMGN

About ImmunoGen, Inc.


  • Ticker IMGN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 220,712,992
  • Description
  • ImmunoGen, Inc., a clinical-stage biotechnology company, develops antibody-drug conjugate (ADC) therapies to treat cancer. The company's product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha (FRa), which is in Phase III clinical trial for the treatment of platinum-resistant ovarian cancer; and Pivekimab sun...
More about IMGN
Track This Portfolio

Track Peak6 Investments LLC Portfolio

Follow Peak6 Investments LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Peak6 Investments LLC, based on Form 13F filings with the SEC.

News

Stay updated on Peak6 Investments LLC with notifications on news.